natgillin/translations-raw huggingface dataset:
• if you have problems with your pancreas, stomach or gut (‘intestines') - these organs are responsible for absorption of glycerol phenylbutyrate into the body.
• če imate težave s trebušno slinavko, želodcem ali prebavili - ti organi so odgovorni za absorpcijo glicerol fenilbutirata v telesu.
Patients were required to have a diagnosis of UCD involving deficiencies of CPS, OTC, or ASS, confirmed via enzymatic, biochemical, or genetic testing.
Bolniki so morali imeti potrjeno diagnozo motnje ciklusa sečnine, ki vključuje pomanjkanje CPS, OTC ali ASS, potrjene z encimskimi, biokemičnimi ali genetskimi preiskavami.
If you take more of this medicine than you should, talk to a doctor.
Če vzamete več zdravila, kot bi smeli, se morate takoj posvetovati z zdravnikom.
Turn the bottle upside down with the oral syringe still inserted.
Steklenico obrnite z glavo navzdol, pri čemer je peroralna brizga še vedno vstavljena.
The liquid is filled into a 25 ml clear glass bottle and capped with a plastic, child-resistant cap.
Tekočina je polnjena v 25 ml steklenico iz prozornega stekla, ki se zapre s plastičnim, za otroke varnim zapiralom.
• tests show low albumin in your blood
• preiskave, ki kažejo nizke vrednosti albumina v krvi
When taking glycerol phenylbutyrate you may feel dizzy or have a headache.
V času jemanja glicerol fenilbutirata ste lahko omotični ali imate glavobol.
In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other medicinal product therapy.
Na splošno je treba pazljivo določiti odmerek za starejšega bolnika, pri čemer je treba začeti odmerjati pri spodnji meji razpona odmerjanja zaradi večje pogostosti zmanjšanega delovanja jeter, ledvic ali srca ali sočasnih bolezni ali zdravljenja z drugimi zdravili.
A decision must be made whether to discontinue breastfeeding or to discontinue/abstain from glycerol phenylbutyrate therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja z glicerol fenilbutiratom, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
• Hypersensitivity to the active substance.
• Preobčutljivost na učinkovino.
PAA clearance was 7.1 L/h, 10.9 L/h, 16.4 L/h, and 24.4 L/h, respectively, for UCD patients ages ≤ 2, 3 to 5, 6 to 11, and 12 to 17 years.
Očistek PAA je bil 7,1 l,/h, 10,9 l/h, 16,4 l/h in 24,4 l/h, za bolnike z UCD starosti ≤ 2, 3 do 5, 6 do 11 in 12 do 17 let.
Glycerol phenylbutyrate given at the maximum recommended dose contains less than 0.5 g of glycerol per dose.
Glicerol Glicerol fenilbutirat pri največjem priporočenem odmerku vsebuje manj kot 0,5 g glicerola na odmerek.
After you take your full dose, have a drink of water to make sure no medicine is left in your mouth, or flush the gastrostomy or nasogastric tube with 10 ml of water using a new oral syringe.
Po zaužitju polnega odmerka zdravila popijte kozarec vode, da ne ostane kaj zdravila v ustih ali splaknite gastrostomo ali nazogastrično sondo z 10 ml vode in pri tem uporabite novo peroralno brizgo.
These findings collectively indicate that conversion of PAA to PAGN may be impaired in patients with severe hepatic impairment and that a plasma PAA to PAGN ratio > 2.5 identifies patients at risk of elevated PAA levels.
Ti izsledki skupaj nakazujejo, da je pretvorba PAA v PAGN lahko ovirana pri bolnikih s hudo okvaro jeter in da razmerje med plazemsko PAA in PAGN, ki znaša > 2,5, opredeljuje bolnike s tveganjem za povišane ravni PAA.
Wye Valley Business Park Brecon Road
Wye Valley Business Park
Hyperammonemic crises were precipitated by vomiting, upper respiratory tract infection, gastroenteritis, decreased caloric intake or had no identified precipitating event (3 events).
Hiperamoniemične krize so se pojavile po bruhanju, okužbi zgornjih dihal, gastroenteritisu, zmanjšanemu kaloričnemu vnosu ali pa pred tem ni bilo opredeljenih dogodkov (3 dogodki).
Do not stop taking glycerol phenylbutyrate without talking to your doctor.
Ne prenehajte jemati glicerol fenilbutirata brez predhodnega posveta z zdravnikom.
RAVICTI may have major influence on the ability to drive and use machines given that treatment with glycerol phenylbutyrate may cause dizziness or headaches (see section 4.8).
Zdravilo RAVICTI lahko ima pomemben vpliv na sposobnost vožnje in upravljanja s stroji, saj lahko zdravljenje z glicerol fenilbutiratom lahko povzroči omotico ali glavobole (glejte poglavje 4.8).
Assessment of adverse reactions was based on exposure in 114 UCD patients (65 adults and 49 children between the ages of 2 months and 17 years) with deficiencies in CPS, OTC, ASS, ASL, ARG, or HHH across 4 short term and 3 long term clinical studies, in which 90 patients completed 12 months duration (median exposure = 51 weeks).
Ocena neželenih učinkov je temeljila na izpostavljenosti 114 bolnikov z UCD (65 odraslih in 49 otrok, starih od 2 mesecev do 17 let) s pomanjkanjem CPS, OTC, ASS, ASL, ARG ali s HHH v 4 kratkoročnih in 3 dolgoročnih kliničnih študijah, v katerih je 90 bolnikov zaključilo 12-mesečno obdobje (povprečna izpostavljenost = 51 tednov).
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON (STANDARD PACK)
PODATKI NA ZUNANJI OVOJNINI ZUNANJA ŠKATLA (STANDARDNO PAKIRANJE)
Although these have not been seen in clinical trials involving UCD patients, high PAA levels should be suspected in patients (particularly in children <2months) with unexplained somnolence, confusion, nausea and lethargy who have normal or low ammonia.
Čeprav te manifestacije niso bile opažene v kliničnih preskušanjih, ki so vključevala bolnike z UCD, je treba pri bolnikih (zlasti pri otrocih < 2 meseca) z nepojasnjeno somnolenco, zmedenostjo, slabostjo in letargijo, pri katerih je raven amoniaka normalna ali nizka, posumiti na visoke ravni PAA.
• increased temperature, hot flushes
• povišana telesna temperatura, vročinski oblivi
• Utilise an oral syringe to withdraw the prescribed dosage of RAVICTI from the bottle.
• Uporabite peroralno brizgo za odvzem predpisanega odmerka zdravila RAVICTI iz steklenice.
In healthy adult volunteers, a gender effect was found for all metabolites, with women generally having higher plasma concentrations of all metabolites than men at a given dose level.
Spol Pri zdravih odraslih prostovoljcih je bil učinek spola ugotovljen pri vseh presnovkih, pri čemer so ženske imele višje plazemske koncentracije vseh presnovkov kot moški pri določenem odmerku.
In such cases, increasing the dosing frequency may result in a lower plasma PAA level and PAA to PAGN ratio.
V takšnih primerih lahko zvišanje pogostosti odmerjanja posledično zniža raven plazemske PAA in razmerje med PAA in PAGN.
In healthy subjects, the systemic exposure to PAA, PBA, and PAGN increased in a dose dependent manner.
Pri zdravih preiskovancih se je sistemska izpostavljenost PAA, PBA in PAGN zvišala odvisno od velikosti odmerka.
UCDs are inherited deficiencies of enzymes or transporters necessary for the synthesis of urea from ammonia (NH3, NH4+).
Motnje ciklusa sečnine so dedne okvare encimov ali prenašalcev, ki so potrebni za sintezo sečnine iz amoniaka (NH3, NH4+).
• Flush once with 10 ml of water or medical formula and allow the flush to drain after administration.
• Po aplikaciji sperite enkrat z 10 ml vode ali medicinskim pripravkom in pustite, da tekočina odteče.
The median exposure was 10 months (range 2 to 20 months).
Mediana izpostavljenosti je bila 10 mesecev (razpon 2 meseca do
The recommended daily dose schedule of 8.5 ml/m2/day - 11.2 mL/m2/day over a period of up to 24 hours for patients stabilised with no further hyperammonaemia is as follows:
Priporočeni načrt dnevnega odmerjanja 8,5 ml/m2/dan - 11,2 ml/m2/dan v do 24-urnem obdobju za stabilizirane bolnike, ki več nimajo hiperamoniemije, je
RAVICTI may be added to a small amount of apple sauce, ketchup, or squash puree and should be used within 2 hours when stored at room temperature (25° C).
Zdravilo RAVICTI se lahko doda manjši količini jabolčne čežane, kečapa ali bučnega pireja in ga je treba porabiti v 2 urah, če je shranjeno pri sobni temperaturi (25 °C).
Population pharmacokinetic modelling and dosing simulations suggest body surface area is the most significant covariate explaining the variability of PAA clearance.
Farmakokinetično modeliranje in simulacije odmerkov v populaciji nakazujejo, da je telesna površina najpomembnejša sospremenljivka, ki pojasnjuje variabilnost očistka PAA.
Further adjustment may be based on monitoring of plasma ammonia, glutamine, U-PAGN and/or plasma PAA and PAGN as well as the ratio of plasma PAA to PAGN (see section 4.2).
Nadaljnje prilagoditve lahko temeljijo na plazemskem amoniaku, glutaminu, U-PAGN in/ali plazemski PAA in PAGN kot tudi na razmerju med plazemsko PAA in PAGN (glejte poglavje 4.2).
PAA, the active metabolite of glycerol phenylbutyrate, is associated with signs and symptoms of neurotoxicity (see section 4.4) and could accumulate in patients who receive an overdose.
PAA, aktivni presnovek glicerol fenilbutirata, je povezan z znaki in simptomi nevrotoksičnosti (glejte poglavje 4.4) in se lahko nakopiči pri bolnikih, ki zaužijejo prevelik odmerek zdravila.
• 9000 microgram (mcg/ml) for patients under 2 years of age
• 9000 mikrogramov (μg/ml) za bolnike, mlajše od 2 let
In some cases such as infection or post-surgery, the amount of ammonia may go up despite treatment with this medicine and may damage the brain (hyperammonaemic encephalopathy).
V določenih primerih, kot je okužba ali po operaciji, se lahko raven amoniaka zviša kljub zdravljenju z glicerol fenilbutiratom in lahko poškoduje možgane (hiperamoniemična encefalopatija).
It is a triglyceride containing 3 molecules of PBA linked to a glycerol backbone.
Je triglicerid, ki vsebuje 3 molekule PBA, ki so vezane na osnovo glicerola.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Druga zdravila in zdravilo RAVICTI Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
• In urea cycle disorders, the body is not able to produce enough liver enzymes to remove the extra nitrogen.
• Pri motnjah ciklusa sečnine telo ne zmore proizvajati zadostne količine jetrnih encimov za odstranitev odvečnega dušika.
One oral syringe should be used each day.
Vsak dan se uporabi ena peroralna brizga.
If spot U-PAGN concentrations fall below these levels, assess compliance with medicinal product and/or effectiveness of medicinal product administration (e.g., via feeding tube) and consider increasing the glycerol phenylbutyrate dose in compliant patients to achieve optimal ammonia control (within normal limit for patients under 2 years of age and less than half ULN in older patients when fasted).
Če stopnja koncentracije U-PAGN ob posameznih meritvah pade pod te ravni, ocenite bolnikovo zmožnost jemanja zdravila in/ali učinkovitost aplikacije zdravila (npr. po cevki za hranjenje) in razmislite o zvišanju odmerka glicerol fenilbutirata pri bolnikih, ki zdravilo jemljejo ustrezno, da bi dosegli optimalen nadzor ravni amoniaka (znotraj meje normalne vrednosti za bolnike, mlajše od 2 let, in na manj kot polovici ULN pri starejših bolnikih na tešče).
After the last dose of the day, the oral syringe should be discarded.
Po zadnjem dnevnem odmerku je treba peroralno brizgo zavreči.
RAVICTI can be added to a small amount of soft foods, such as ketchup, medical formulas, apple sauce or squash puree.
Zdravilo RAVICTI lahko dodate manjšim količinam mehke hrane, kot so kečap, medicinski pripravki, jabolčna čežana ali bučni pire.
This corresponds to a density of 1.1 g/ml.
To ustreza gostoti 1,1 g/ml.
In these in vitro studies, a complete disappearance of glycerol phenylbutyrate did not produce molar equivalent PBA, suggesting the formation of mono- or bis-ester metabolites.
V tej študijah in vitro popolno izginotje glicerol fenilbutirata ni ustvarilo molarno ekvivalentne količine PBA, kar nakazuje na tvorbo mono- ali bis estrnih presnovkov.
RAVICTI contains the active substance ‘glycerol phenylbutyrate' which is used to treat six known ‘urea cycle disorders' (UCDs) in adults and children.
Zdravilo RAVICTI vsebuje učinkovino »glicerol fenilbutirat«, ki se uporablja za zdravljenje šestih znanih motenj ciklusa sečnine (UCD, urea cycle disorders) pri odraslih in otrocih.
The mean (SD) percentage of administered PBA eliminated as PAGN was approximately 68.9% (17.2) in adults and 66.4% (23.9) in paediatric UCD patients at steady state.
Povprečni odstotek (SD) apliciranega PBA, ki se izloči kot PAGN, je bil približno 68,9 % (17,2) pri odraslih in 66,4 % (23,9) pri otrocih z UCD v stanju dinamičnega ravnovesja.
In this case, glycerol phenylbutyrate will not stop the level of ammonia in your blood from becoming seriously high.
V tem primeru glicerol fenilbutirat ne bo preprečil prekomernega zvišanja ravni amoniaka v krvi.
RAVICTI should be taken with meals and administered directly into the mouth via an oral syringe.
Zdravilo RAVICTI je treba zaužiti z obroki in aplicirati neposredno v usta po peroralni brizgi.
Compatibility studies have demonstrated glycerol phenylbutyrate chemical and physical in-use stability with the following foods and nutritional supplements: apple sauce, ketchup, squash puree, and five medical formulas (Cyclinex-1, Cyclinex-2, UCD-1, UCD-2, Polycose, Pro Phree and Citrulline) typically consumed by UCD patients (see section 4.2).
Študije o združljivosti so pokazale kemično in fizično stabilnost glicerol fenilbutirata z naslednjimi živili in prehranskimi dopolnili: jabolčna čežana, kečap, bučni pire in pet medicinskih pripravkov (Cyclinex-1, Cyclinex-2, UCD-1, UCD-2, Polycose, Pro Phree in Citrulline), ki jih običajno uživajo bolniki z UCD (glejte poglavje 4.2).
PAA conjugates with glutamine (which contains 2 molecules of nitrogen) via acetylation in the liver and kidneys to form PAGN, which is excreted by the kidneys.
PAA konjugira z glutaminom (ki vsebuje 2 molekuli dušika) preko acetilacije v jetrih in ledvicah in tvori PAGN, ki se izloča skozi ledvice.
The most frequently reported adverse reactions (>5%) during glycerol phenylbutyrate treatment were diarrhoea, flatulence, and headache (8.8% each); decreased appetite (7.0%), vomiting (6.1%); and fatigue, nausea and, skin odour abnormal (5.3% each).
Najpogostejši neželeni učinki (> 5 %) v času zdravljenja s fenilbutiratom so bili driska, flatulenca in glavobol (8,8 % vsak), zmanjšan apetit (7,0 %), bruhanje (6,1 %) in utrujenost, slabost in nenavaden telesni vonj (5,3 % vsak).
High levels of ammonia leads to feeling sick (nausea), being sick (vomiting) or feeling confused.
Visoke koncentracije amoniaka vodijo do siljenja na bruhanje (navzea), bruhanja ali občutka zmedenosti.
N-acetylglutamate synthase (NAGS) and CITRIN (citrullinaemia type 2) deficiency The safety and efficacy of RAVICTI for the treatment of patients with N-acetylglutamate synthase (NAGS) and CITRIN (citrullinaemia type 2) deficiency have not been established.
Pomanjkanje N-acetilglutamat sintaze (NAGS )in CITRIN (citrulinemija tipa 2) Varnost in učinkovitost zdravila RAVICTI pri zdravljenju bolnikov s pomanjkanjem N-acetilglutamat sintaze in citrulinemijo tipa 2 nista bili dokazani.
• corticosteroids - used to treat inflamed areas of the body
• kortikosteroidi - uporabljajo se za zdravljenje vnetih mest na telesu
• In urea cycle disorders, the body cannot remove the nitrogen from the protein that we eat.
• Pri motnjah ciklusa sečnine telo ne zmore odstraniti dušika iz beljakovin, ki jih zaužijemo.
• increased number of platelets (tends to cause blood clot)
• zvišano število trombocitov (ki povzročajo strjevanje krvi)
• lipase in pancreatic replacement therapies
• lipaze pri nadomestnih zdravljenjih bolezni trebušne slinavke
There was one additional patient who had one venous ammonia level that exceeded 100 micromol/L which was not associated with a hyperammonemic crisis.
Pri enem dodatnem bolniku so opazili eno raven amoniaka v venski krvi, ki je bila višja od 100 mikromolov/l, in ni bila povezana s hiperamoniemično krizo.
What you need to know before you take RAVICTI Do not take RAVICTI:
Kaj morate vedeti, preden boste vzeli zdravilo RAVICTI Ne jemljite zdravila RAVICTI:
• There are no other ingredients.
• Drugih sestavin zdravilo ne vsebuje.
In patients with a PAA to PAGN ratio exceeding 2.5, a further increase in glycerol phenylbutyrate dose may not increase PAGN formation, even if plasma PAA concentrations are increased, due to saturation of the conjugation reaction.
Pri bolnikih, pri katerih razmerje med PAA in PAGN presega 2,5, nadaljnje zvišanje odmerka glicerol fenilbutirata ne sme zvišati tvorbe PAGN, četudi so koncentracije PAA povečane zaradi nasičenosti konjugacijske reakcije.
Therefore, dosage for adult and paediatric patients with mild, moderate or severe hepatic impairment should be started at the lower end of the recommended dosing range (4.5 ml/m2/day) and kept at the lowest dose necessary to control the patient's ammonia levels.
Zato mora biti začetni odmerek za odrasle in otroke z blago, zmerno ali hudo okvaro jeter na spodnji ravni priporočenega razpona odmerjanja (4,5 ml/m2/na dan) ter ga je treba obdržati na najnižji ravni, ki je potrebna za nadzor ravni amoniaka.
In a juvenile rat study with daily oral dosing performed on postpartum day 2 through mating and pregnancy after maturation, terminal body weight was dose-dependently reduced in males and females, by up to 16% and 12% respectively.
V študiji na mladičih živalih z dnevnimi peroralnimi odmerki od 2. dne po skotitvi do parjenja in brejosti po doseganju zrelosti, se je končna telesna masa zmanjšala odvisno od odmerka, pri samcih do 16 % in pri samicah do 12 %.
Glycerol phenylbutyrate has been tested in a range of in vitro and in vivo genotoxicity studies, and shown no genotoxic activity.
Glicerol fenilbutirat je bil testiran v številnih študijah genotoksičnosti in vitro ter in vivo in ni izkazoval genotoksične aktivnosti.
Hyperammonaemia was reported in 5 (50%) subjects age < 1 month (all serious but non-fatal) and 1 subject (16.7%) age 1-2 months (non-serious), which is consistent with more severe disease types diagnosed in the neonatal period.
O hiperamonemiji so poročali pri 5 (50 %) preizkušancih, starih < 1 mesec (vsi resni, a ne smrtni) in pri 1 preizkušancu (16,7 %), starem 1-2 meseca (neresen), kar je skladno z bolj resno obliko bolezni,
No developmental abnormalities were observed in rats through day 92 postpartum following oral administration in pregnant rats, during organogenesis and lactation.
Razvojnih nepravilnosti niso opazili pri podganah do 92. dne po skotitvi po peroralni aplikaciji brejim podganam, v času organogeneze in dojenja.
The amount of dose adjustment should factor in the amount of dietary protein that has not been covered, as indicated by the 24-h U-PAGN level and the estimated glycerol phenylbutyrate dose needed per gram of dietary protein ingested.
Količina prilagoditve odmerka mora upoštevati količino prehranskih beljakovin, ki ni bila pokrita, kot je določeno za raven U-PAGN v 24 urah, in ocenjen odmerek glicerol fenilbutirata, ki je potreben na gram zaužitih prehranskih beljakovin.
• poor feeding
• zmanjšan vnos hrane
Effects of glycerol phenylbutyrate on other CYP isoenzymes have not been studied in humans and cannot be excluded.
Učinkov glicerol fenilbutirata na druge izoencime CYP pri ljudeh niso raziskovali, zato jih ni možno izključiti.
The plasma PAA to PAGN ratio may be useful in dosage monitoring.
Razmerje med plazemsko PAA in PAGN je lahko uporabno pri nadzorovanju odmerjanja.
Hereford, Herefordshire, HR3 5PG United Kingdom
Hay-on-Wye, Hereford, Herefordshire, HR3 5PG
In in vitro studies, the specific activity of lipases for glycerol phenylbutyrate was seen in the following decreasing order: pancreatic triglyceride lipase, carboxyl ester lipase, and pancreatic lipase-related protein 2.
V študijah in vitro je bila specifična aktivnost lipaz za glicerol fenilbutirat opažena v naslednjem padajočem vrstnem redu: pankreatična trigliceridna lipaza, karboksil ester lipaza in lipaze trebušne slinavke PLRP2 (pancreatic lipase-related protein 2).
Patients had to have no clinical evidence of hyperammonaemia at enrolment and were not allowed to receive medicinal products known to increase ammonia levels (e.g., valproate), increase protein catabolism (e.g., corticosteroids), or significantly affect renal clearance (e.g., probenecid).
Ob vključitvi bolniki niso smeli imeti klinično potrjene hiperamoniemije in niso smeli jemati zdravil, ki zvišujejo raven amoniaka (npr. valproat), pospešujejo razgradnjo beljakovin (npr. kortikosteroidi) ali pomembno vplivajo na ledvični očistek (npr. probenecid).
If symptoms of vomiting, nausea, headache, somnolence, confusion, or sleepiness are present in the absence of high ammonia or other intercurrent illnesses, measure plasma PAA and plasma PAA to PAGN and consider reduction of glycerol phenylbutyrate dosage or increase the frequency of dosing if the PAA level exceeds 500 mcg/L and the plasma PAA to PAGN ratio exceeds 2.5.
Če so simptomi, kot so bruhanje, slabost, glavobol, somnolenca, zmedenost ali zaspanost, prisotni ob odsotnosti visokih ravni amoniaka ali drugih trenutnih bolezni, izmerite plazemsko PAA in plazemsko pretvorbo PAA v PAGN ter razmislite o znižanju odmerka glicerol fenilbutirata oziroma povečanju pogostnosti odmerjanja, če raven PAA preseže 500 μg/ml in razmerje med PAA in PAGN preseže 2,5.
Open the bottle of RAVICTI by pushing down on the cap and twisting to the left.
Steklenico z zdravilom RAVICI odprite tako, da zamašek potisnete dol in ga obrnete v levo.
RAVICTI is a pro-drug of PBA.
Zdravilo RAVICTI je predzdravilo PBA.
You will need to take this medicine and follow a special low protein diet throughout your life.
To zdravilo boste morali jemati celo življenje in upoštevati posebno dieto z malo beljakovinami.
Of the 45 paediatric patients participating in the open-label treatment with glycerol phenylbutyrate, 11 patients (24%) reported a total of 22 hyperammonemic crises.
Od 45 pediatričnih bolnikov, ki so sodelovali v odprtem zdravljenju z glicerol fenilbutiratom, je 11 bolnikov (24 %) poročalo o skupaj 22 hiperamoniemičnih krizah.
The pharmacokinetics of glycerol phenylbutyrate in patients with impaired renal function, including those with end-stage renal disease (ESRD) or those on haemodialysis, have not been studied.
Farmakokinetične lastnosti glicerol fenilbutirata pri bolnikih z okvaro ledvic, vključno s tistimi s končno odpovedjo ledvic (ESRD, end-stage renal disease), ali tistimi na hemodializi, niso bile raziskane.
• through a tube that goes through your nose to the stomach - called a ‘nasogastric tube'
• skozi cevko, ki gre skozi vaš nos do želodca - nazogastrična sonda
The medicinal product may be mixed with medical formulas (Cyclinex-1, Cyclinex-2, UCD-1, UCD-2, Polycose, Pro Phree and Citrulline) and used within 2 hours when stored at 25° C, or up to 24 hours, refrigerated.
To zdravilo se lahko meša z medicinskimi pripravki (Cyclinex-1, Cyclinex-2, UCD-1, UCD-2, Polycose, Pro Phree in Citrulline) in ga je treba uporabiti v 2 urah, če je shranjeno pri sobni temperaturi 25 °C, ali v 24 urah, če je shranjeno v hladilniku.
In healthy female volunteers, mean Cmax for PAA was 51% and 120% higher than in male volunteers after administration of 4 ml and 6 ml 3 times daily for 3 days, respectively.
Pri zdravih ženskih prostovoljkah je bila povprečna vrednost Cmax PAA za 51 % oz. 120 % višja kot pri moških prostovoljcih po aplikaciji 4 ml in 6 ml trikrat na dan.
Probenecid Probenecid may inhibit the renal excretion of metabolites of glycerol phenylbutyrate including PAGN.
Probenecid Probenecid lahko zavira ledvično izločanje presnovkov glicerol fenilbutirata, vključno s PAGN.